Synopsis of recent research by authors named "So Yeong Kwon"
- So Yeong Kwon's research primarily focuses on the development of novel compounds targeting anaplastic lymphoma kinase (ALK) for anticancer therapies, particularly through the synthesis of bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines.
- The compound KRCA-0008 has been found to be a potent and selective ALK inhibitor, demonstrating significant in vivo efficacy that is comparable to the established drug Crizotinib in xenograft mouse models.
- Kwon's findings also emphasize the favorable drug-like properties of KRCA-0008, noting its selectivity and low liability for hERG channel inhibition, which is crucial for the safety profiles of potential anticancer drugs.
